Navigation Links
ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis
Date:12/7/2009

MINNEAPOLIS, Dec. 7 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ATSI), manufacturer and marketer of state-of-the-art cardiac surgery products and services today announced it has received CE Mark approval to distribute the ATS 3f Enable® Aortic Bioprosthesis in the European Union, indicating it is compliant with relevant European health, safety, and environmental protection legislation. The Enable valve is the first surgical aortic valve replacement approved for commercial use that is implanted using a sutureless technique. It is the first valve of the ATS 3f Enable platform which combines the novel 3f tubular pericardial valve design with its superior hemodynamic profiles and a self-expanding frame to hold the valve in its optimal position.

The goal of the Enable valve is to achieve a less invasive aortic valve replacement and reduce procedure times. Today, most aortic valve surgery cannot be done on a minimally invasive basis because precise suturing is difficult within the confined space of a minimally invasive procedure. The sutureless Enable valve can be folded into a small diameter to allow placement through a minimally invasive incision. Once the Enable valve is delivered to the site of the annulus, it is expanded to its preconfigured diameter and is held in place with a resistance fit.

"We have been implanting the ATS Enable valve for four years achieving excellent hemodynamic and safety results. This valve is an important step toward the goal of reducing procedure time and allowing for a more minimally invasive approach to conventional valve surgery," stated Professor Jerzy Sadowski MD, PhD, Jagiellonian University, Department of CV Surgery and Transplantology, Krakow, Poland. Professor Sadowski and his surgical team performed the first human implant of the Enable valve in January 2005.
'/>"/>

SOURCE ATS Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Alberta companies delivering new products to the health & medical marketplace
2. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
3. Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures
4. Gamida Cell Announces Feasibility Study With Weill Cornell Medical College
5. New Jerseys Best and Brightest Minds Discuss Challenges Facing Medical Innovation, Call for Policies to Preserve U.S. Leadership in Research and Development
6. PacsDrive Announces Low Cost Medical Imaging Storage Service, Seeks to Alter Status Quo in Health Care IT
7. Aethlon Medical to Present at LD MICRO Conference on December 3, 2009
8. China Sky One Medical, Inc. Signs Distribution Agreement with MDK for the Sale of Two Diagnostic Kits in Southeast Asia
9. ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ
10. Exiqon Recognizes Harvard Medical School Core Facility as MicroRNA Screening Center of Excellence
11. Elsevier is Re-Launching "Embase" to be a Powerful Resource Providing Deep Insights and Answers to Biomedical Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... LEXINGTON, Mass. , April 21, 2015 ... company developing transformative pharmaceutical products for subcutaneous ... its pivotal trial of its investigational proprietary ... treatment of edema associated with congestive heart ... development, scPharmaceuticals is developing a proprietary patch ...
(Date:4/21/2015)... Thornton Cleveleys (UK) (PRWEB) April 21, 2015 ... PEEK* technology and its clinical applications will ... Meeting. Participants include engineers, scientists, regulators and ... worldwide. The meeting is sponsored by Invibio ... PEEK polymer-based biomaterials, a specialist in manufacturing ...
(Date:4/20/2015)... MENLO PARK, Calif. , April 20, ... DMPI) (DelMar and the Company), a biopharmaceutical company ... in new orphan drug indications, today announced promising ... of the American Association for Cancer Research ... lead product candidate VAL-083 (dianhydrogalactitol) to ...
(Date:4/20/2015)... 2015  Eli Lilly and Company (NYSE: LLY ... cancer therapies, reflecting Lilly,s diverse oncology pipeline, during the ... held April 18-22 in Philadelphia , ... is the theme of this year,s AACR meeting and ... its portfolio of therapies that accelerate the pace and ...
Breaking Biology Technology:scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 2scPharmaceuticals Announces Start of Pivotal Trial for Novel Furosemide Solution for Subcutaneous Delivery 32nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 22nd International PEEK Meeting: Invibio Biomaterial Solutions spearheads medical research for implantable PEEK polymer devices 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 2DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 3DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 4DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM) 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6
... RICHARDSON, Texas, Aug. 21 Zyvex Labs today ... company was started by Rob,Burgess, PhD, former Vice ... Gareth Hughes, PhD, former Group Leader of Life ... the application of nanotechnology in Life,Sciences. The company ...
... BOSTON and THE WOODLANDS, Texas, Aug. 21 ... presented data today,describing the structure-activity relationship (SAR) ... LX1031 and other compounds,under evaluation by the ... (IBS) and other gastrointestinal disorders. LX1031 is ...
... PITTSBURGH, Aug. 21 The Pittsburgh Life ... life,sciences industry on a fast track for growth, ... $450,000 in three companies: Applied Computational,Technologies, Separation Design ... to identifying and making investments in promising,life sciences ...
Cached Biology Technology:NanoMed, Inc. Spins Out of Zyvex Labs 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 2Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome 3The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio 2The Pittsburgh Life Sciences Greenhouse Adds New Companies to its Investment Portfolio 3
(Date:4/17/2015)... 17, 2015 Increasing ... technological advancement to drive biometric systems market in ...   According to a recently released ... &  Opportunities, 2020 ", biometric systems market in ... growth at CAGR of over 22% through 2020. ...
(Date:4/13/2015)... , April 13, 2015  higi, a leading ... ways to more fully engage with their communities around ... industry-leading, privacy protected and secure API.  ... enables the most accessible, affordable, and convenient vehicle to ... The API will allow ...
(Date:4/6/2015)... OXFORD, Conn. , Apr. 6, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/143028 for ... CLOSE-PROXIMITY COMMUNICATIONS AND ENERGY TRANSFER  NXT-ID introduces ... wireless payments. This patent surrounds the use of ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... the buzzword "nano" - cancer detection using nanoparticles and ... cancers is one of the most important parts of ... and determination,of the most appropriate treatment. And an essential ... there has been lymphatic spread. Current,methods include surgical removal ...
... target for a drug seems very promising on paper; ... of telomerase inhibitors,to treat cancer; they are supposed to ... cells. Yet, something in the cell,seems to block their ... do then? Scrap the project? Look for something,else? Hell ...
... drugs that keep the HIV-virus infection from progressing to ... disturbances in some patients. The finding of a Mayo ... The Lancet. , In collaboration with colleagues from the ... University of Minnesota, Minneapolis, and University of Wisconsin, Madison, ...
Cached Biology News:Imaging Lymph Nodes with Nanoparticles 2GATA: a graphic alignment tool for comparative sequence analysis 2HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs 2HIV Patients May Be at Risk of Heart Problems When Taking Protease Inhibitor Drugs 3
Request Info...
Request Info...
Limit of detection: <5 pg/ml...
... custom siRNA service provides the premium quality ... research. Custom siRNAs can be readily ordered ... target sequence, or by providing the sense ... Ambion's Silencer Validated and Silencer Pre-designed siRNAs, ...
Biology Products: